Compare Match Group Inc (MTCH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs GeneDx Holdings Corp — how do they compare? Match Group Inc trades at $41.48 (market cap $9.53B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Match Group Inc is far larger — about 4.7× GeneDx Holdings Corp's market cap, and Match Group Inc pays a 1.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and GeneDx Holdings Corp for 19 Days on average.
| MTCH | WGS | |
|---|---|---|
Market Cap | $9.53B | $2.02B |
Volume | 3,228,794 | 734,640 |
Sector | Media | Health |
52-Week High | $44.40 | $167.51 |
52-Week Low | $28.90 | $34.51 |
Typical Hold Time | 115 Days | 19 Days |
Enterprise Value | $12.49B | $2.05B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a P/E of 14.71, net income margin of 20.17%, and consistent cash flow generation. Recent earnings beat expectations in Q2 2026, and positive news highlights product innovation and growth in Hinge.
The outlook is positive, supported by margin expansion and strategic initiatives, but risks include high debt levels and competitive pressures. Wall Street sentiment is bullish with a $42.29 price target, offering modest upside from current levels.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
